Document is current
Any future updates will be listed below
-
Authors
Huang, Jie
Huffman, Jennifer E. https://orcid.org/0000-0002-9672-2491
Huang, Yunfeng
Do Valle, Ítalo https://orcid.org/0000-0002-6037-3103
Assimes, Themistocles L. https://orcid.org/0000-0003-2349-0009
Raghavan, Sridharan
Voight, Benjamin F.
Liu, Chang
Barabási, Albert-László
Huang, Rose D. L.
Hui, Qin https://orcid.org/0000-0002-8421-3518
Nguyen, Xuan-Mai T.
Ho, Yuk-Lam https://orcid.org/0000-0003-3305-3830
Djousse, Luc
Lynch, Julie A. https://orcid.org/0000-0003-0108-2127
Vujkovic, Marijana https://orcid.org/0000-0003-4924-5714
Tcheandjieu, Catherine https://orcid.org/0000-0001-9559-4339
Tang, Hua https://orcid.org/0000-0002-0177-8864
Damrauer, Scott M.
Reaven, Peter D. https://orcid.org/0000-0001-8923-6690
Miller, Donald https://orcid.org/0000-0002-7881-8801
Phillips, Lawrence S. https://orcid.org/0000-0002-6542-8046
Ng, Maggie C. Y. https://orcid.org/0000-0002-4133-2007
Graff, Mariaelisa
Haiman, Christopher A.
Loos, Ruth J. F. https://orcid.org/0000-0002-8532-5087
North, Kari E. https://orcid.org/0000-0002-8903-0366
Yengo, Loic https://orcid.org/0000-0002-4272-9305
Smith, George Davey https://orcid.org/0000-0002-1407-8314
Saleheen, Danish
Gaziano, J. Michael
Rader, Daniel J. https://orcid.org/0000-0002-9245-9876
Tsao, Philip S. https://orcid.org/0000-0001-7274-9318
Cho, Kelly
Chang, Kyong-Mi https://orcid.org/0000-0001-6811-9364
Wilson, Peter W. F.
,
Sun, Yan V. https://orcid.org/0000-0002-2838-1824
O’Donnell, Christopher J. https://orcid.org/0000-0002-2667-8624
- License Information
-
More Information
Article History
Received: 8 May 2022
Accepted: 9 December 2022
First Online: 29 December 2022
Competing interests
: C.J.O’D. is employed by Novartis Institutes for Biomedical Research. P.D.R. has received research grant support from the following for-profit companies: Bristol Myers Squib, Lysulin Inc; and has consulted with Intercept Pharmaceuticals and Boston Heart Diagnostics. D.S. has received support from the British Heart Foundation, Pfizer, Regeneron, Genentech, and Eli Lilly pharmaceuticals. L.S.P. declares that there is no duality of interest associated with this manuscript. With regard to potential conflicts of interest, L.S.P. has served on Scientific Advisory Boards for Boehringer Ingelheim and Janssen, and has or had research support from Merck, Pfizer, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, and the Cystic Fibrosis Foundation. L.S.P. is also a cofounder and Officer and Board member and stockholder of a company, Diasyst, Inc., which markets software aimed to help improve diabetes management. S.M.D receives research support from Renalytix AI and Novo Nordisk to the University of Pennsylvania and consulting fees from Calico Labs. A.-L.B. is co-scientific founder of and is supported by Scipher Medicine, Inc. G.D.S. is a member of the Scientific Advisory Boards of Relation Therapeutics and Insitro. The remaining authors declare no competing interests.
